Cafelkibart Biosimilar - Research Grade

Human

CCR8

>1mg/ml

IgG1 - kappa

CHO Cells

Azirkitug Biosimilar - Research Grade (ICH5368), Denikitug Biosimilar - Research Grade (ICH5474), Lanerkitug Biosimilar - Research Grade (ICH5625)

https://www.imgt.org/mAb-DB/

ICH3002

P51685

1237

Blue ice

This product is a research-grade biosimilar of Cafelkibart, an anti-CCR8 monoclonal antibody. It is supplied as an unconjugated, non-therapeutic analog of the originator molecule, built around the CCR8 target and produced for research use only. The originator Cafelkibart (also referenced in development as LM-108) is a humanized, Fc-optimized IgG1 antibody being investigated in oncology, where the intended mechanism is selective depletion of tumor-infiltrating regulatory T cells that express CCR8. This ichor.bio biosimilar reproduces the target specificity of the originator so that laboratories can use it as a comparator, control, or binding reagent in preclinical and in-vitro workflows, rather than as a clinical drug. It is offered as an IgG1 kappa human-sequence antibody at research grade with low endotoxin, and is available in bulk milligram-to-gram quantities suitable for assay development, functional characterization, and standardization across experiments. It is not a clinical product and is not intended for diagnostic or therapeutic use. Because CCR8 is a human target, the reagent is generally applied in human-cell and in-vitro systems rather than mouse in-vivo dosing studies. CCR8 (C-C chemokine receptor type 8; UniProt P51685) is a seven-transmembrane G-protein-coupled receptor whose principal ligand is the chemokine CCL1. In humans it is expressed on subsets of T cells and, notably, is highly enriched on tumor-infiltrating effector regulatory T cells (Tregs) within the tumor microenvironment, while showing minimal expression on peripheral Tregs and conventional T cells. This restricted expression pattern has made CCR8 an attractive immuno-oncology target: depleting or modulating CCR8-positive intratumoral Tregs is proposed to relieve local immunosuppression and restore antitumor CD4 and CD8 T-cell activity, potentially with reduced systemic toxicity compared with broad Treg depletion. CCR8 signaling also contributes to Treg trafficking and retention. Elevated CCR8-positive Treg infiltration has been associated with several solid tumors, including gastric, colorectal, breast, and head and neck cancers.

CC-CKR-8, CCR-8, CDw198, CKRL1, CMKBR8, CMKBRL2, CY6, GPRCY6, TER1, C-C motif chemokine receptor 8

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Cafelkibart (anti-CCR8) Biosimilar

Q: Is the Cafelkibart biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Cafelkibart biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Cafelkibart biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Cafelkibart that binds CCR8; for research use only.